Lifelong PQQ Supplementation Reduces Midlife Mortality Risk in Mice

Researchers at the Department of Biochemistry, Faculty of Pharmaceutical Sciences, have made a significant breakthrough in the quest to improve quality of life and increase lifespan. A research team led by Dr. Keiko Odera and Dr. Ryoya Takahashi, a former professor, conducted a study on senescence-accelerated mouse (SAM) P8 mice, a model commonly used to study the aging process. The study focused on the effects of lifelong supplementation with PQQ (Pyrroloquinoline Quinone) and its derivative IPQ (Isopropyl Pyrroloquinoline Quinone).

The results of the study revealed that lifelong supplementation with PQQ and IPQ significantly reduced mortality risk during midlife in the SAM P8 mice. Furthermore, the study found that this supplementation delayed the progression of aging and age-related decline in muscular function. These findings suggest that PQQ and IPQ may play a crucial role in maintaining physical health and potentially extending lifespan. The research has important implications for the development of new therapeutic strategies to combat age-related diseases and improve quality of life for individuals in aging societies.

The study's findings are a significant step forward in understanding the relationship between PQQ and IPQ and the aging process. Further research is needed to confirm the results and explore the potential applications of these compounds in human health. However, the initial results are promising and highlight the potential of PQQ and IPQ as tools in the fight against age-related decline and the pursuit of a healthier, longer lifespan.